SaxagliptinThird Party Manufacturing in India

Saxagliptin is a potent, selective, and reversible inhibitor of the enzyme dipeptidyl peptidase-4 (DPP-4), which belongs to the gliptin class of oral hypoglycemic agents. DPP-4 is a widely expressed enzyme that rapidly degrades incretin hormones such as glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). These incretin hormones are released from intestinal L-cells and K-cells respectively in response to food intake. By inhibiting DPP-4, saxagliptin prolongs the half-life and increases the circulating levels of active GLP-1 and GIP. Elevated GLP-1 levels enhance glucose-stimulated insulin secretion from pancreatic beta-cells in a glucose-dependent manner — meaning insulin is only released when blood glucose is elevated, reducing the risk of hypoglycemia. GLP-1 also suppresses glucagon secretion from pancreatic alpha-cells, thereby reducing hepatic glucose production. The combined effect of increased insulin and decreased glucagon leads to improved glycemic control with a lower risk of hypoglycemia compared to sulfonylureas or insulin. Additionally, GLP-1 slows gastric emptying, which reduces postprandial glucose excursions. Saxagliptin exhibits approximately 400 to 950-fold selectivity for DPP-4 over related enzymes DPP-8 and DPP-9, which minimizes off-target toxicity concerns.

Therapeutic Uses

Saxagliptin is prescribed for the treatment of:

• Type 2 Diabetes Mellitus: Saxagliptin is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes. It can be used as monotherapy in patients for whom metformin is not tolerated or contraindicated, or as combination therapy with metformin, sulfonylureas, thiazolidinediones, or insulin when glycemic targets are not achieved with monotherapy.

• Combination Therapy: Saxagliptin is particularly effective when used in combination with metformin, as the two drugs address complementary defects in type 2 diabetes — saxagliptin increases incretin-mediated insulin secretion while metformin reduces hepatic glucose production and improves insulin sensitivity.

• Add-on to Insulin: Saxagliptin can be used in combination with insulin (with or without metformin) to improve glycemic control in patients who require insulin therapy.

Why Manufacturers Choose Saxagliptin

Saxagliptin is a well-established DPP-4 inhibitor in the Indian antidiabetic market, widely prescribed as a second-line or add-on therapy in type 2 diabetes management. It has a favorable side effect profile with a low risk of hypoglycemia and weight neutrality, making it a preferred choice over sulfonylureas. The molecule is available as both brand-name and generic formulations across India. Indian API manufacturers produce saxagliptin for the domestic PCD franchise market and for export to emerging markets in Asia, Africa, and Latin America. The growing burden of diabetes in India and worldwide ensures consistent and increasing demand for DPP-4 inhibitors. With the patent expiry of the innovator product, the generic saxagliptin market has expanded significantly, creating opportunities for third party manufacturers and PCD franchise partners. This makes Saxagliptin one of the most sought-after molecules for third party manufacturing in India.